4.8 Review

Targeting the Latent Reservoir for HIV-1

Journal

IMMUNITY
Volume 48, Issue 5, Pages 872-895

Publisher

CELL PRESS
DOI: 10.1016/j.immuni.2018.04.030

Keywords

-

Categories

Funding

  1. NIH [UM1 AI126603, UM1 AI126620, UM1 AI12661]
  2. Johns Hopkins Center for AIDS Research [P30AI094189]
  3. Howard Hughes Medical Institute
  4. Bill and Melinda Gates Foundation [OPP1115715]
  5. Bill and Melinda Gates Foundation [OPP1115715] Funding Source: Bill and Melinda Gates Foundation

Ask authors/readers for more resources

Antiretroviral therapy can effectively block HIV-1 replication and prevent or reverse immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within weeks of treatment interruption. The major barrier to a cure is a small pool of resting memory CD4(+) T cells that harbor latent HIV-1 proviruses. This latent reservoir is now the focus of an intense international research effort. We describe how the reservoir is established, challenges involved in eliminating it, and pharmacologic and immunologic strategies for targeting this reservoir. The development of a successful cure strategy will most likely require understanding the mechanisms that maintain HIV-1 proviruses in a latent state and pathways that drive the proliferation of infected cells, which slows reservoir decay. In addition, a cure will require the development of effective immunologic approaches to eliminating infected cells. There is renewed optimism about the prospect of a cure, and the interventions discussed here could pave the way.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available